Apollomics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Apollomics's earnings have been declining at an average annual rate of -22.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 70.5% per year.
Belangrijke informatie
-22.2%
Groei van de winst
-16.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 70.5% |
| Rendement op eigen vermogen | -274.5% |
| Nettomarge | -2,718.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Apollomics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -57 | 21 | 35 |
| 31 Mar 24 | 1 | -115 | 21 | 34 |
| 31 Dec 23 | 1 | -173 | 21 | 34 |
| 30 Sep 23 | 1 | -280 | 18 | 34 |
| 30 Jun 23 | 1 | -388 | 15 | 34 |
| 31 Mar 23 | 1 | -314 | 12 | 35 |
| 31 Dec 22 | 0 | -241 | 10 | 35 |
| 30 Sep 22 | 0 | -136 | 12 | 35 |
| 30 Jun 22 | 1 | -32 | 13 | 35 |
| 31 Mar 22 | 1 | -63 | 14 | 35 |
| 31 Dec 21 | 0 | -95 | 15 | 36 |
| 31 Dec 20 | 2 | -75 | 11 | 31 |
Kwaliteitswinsten: APLM is currently unprofitable.
Groeiende winstmarge: APLM is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: APLM is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Versnelling van de groei: Unable to compare APLM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: APLM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: APLM has a negative Return on Equity (-274.49%), as it is currently unprofitable.